Individual variations of serum testosterone in patients with prostate cancer receiving androgen-deprivation therapy

BJU International

Volumn 104, Issue 1, 2009, Pages 124-

  Koupparis, Anthony ^a  

^a BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN DERIVATIVE; LEUPRORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; BLOOD SAMPLING; CANCER GROWTH; DRUG TREATMENT FAILURE; LETTER; LUTEINIZING HORMONE BLOOD LEVEL; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

ANDROGEN ANTAGONISTS; HUMANS; LUTEINIZING HORMONE; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 67650473973     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08722-1.x     Document Type: Letter

References (5)

1. Morote J, Planas J, Salvador C et al. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2009 103 : 332 5
2. Smith M, McGovern F. Gonadotropin-releasing hormone agonist failure in a man with prosate cancer. J Urol 2001 166 : 211 (Pubitemid 32565385)
3. Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leupoprolide acetate in locally advanced prostate cancer. Eur Urol 2006 49 : 54 8
4. Koupparis A, Tyrrell C. Non-suppression of testosterone in patients with a rising PSA level receiving luteinising hormone-releasing hormone analogues for metastatic prostate cancer. Clin Oncol 2006 18 : 571
5. Yasukawa K. Leupoprolein acetate granulomas: case reports and review of the literature. Br J Dermatol 2005 152 : 1045 7